1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24024
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPectasides, D.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorKalofonos, C.en
dc.contributor.authorEfstathiou, H.en
dc.contributor.authorFarmakis, D.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorDimopoulos, M. A.en
dc.date.accessioned2015-11-24T19:37:23Z-
dc.date.available2015-11-24T19:37:23Z-
dc.identifier.issn0090-8258-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24024-
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma, Clear Cell/*drug therapy/pathology/surgeryen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCisplatin/administration & dosageen
dc.subjectCombined Modality Therapyen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectCystadenocarcinoma, Serous/*drug therapy/pathology/surgeryen
dc.subjectDoxorubicin/administration & dosageen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/*drug therapy/pathology/surgeryen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectRetrospective Studiesen
dc.subjectSurvival Rateen
dc.titleAdvanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experienceen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/j.ygyno.2005.12.038-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16516283-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0090825805011200/1-s2.0-S0090825805011200-main.pdf?_tid=3e9848d38435cab6a547c7f07b2c76ae&acdnat=1333613418_e738b98042bfb37ba643cbe05ac9a8de-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2006-
heal.abstractPURPOSE: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC). PATIENTS AND METHODS: A retrospective analysis was performed in patients with advanced stage of OCCC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 1/2/1987 and 31/10/2003. The outcome was compared to that of patients with sEOC treated according to the same protocols during the same study period. RESULTS: One hundred and five patients (35 stage III and IV OCCC, 70 stage III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for OCCC was 45% (complete response 25%) (95% CI, 23.1% to 68.5%) and 81% (complete response 46%) (95% CI, 67.4% to 91.1%) for sEOC. The overall response rate was significantly higher for sEOC (P = 0.008). In the subgroup of stage III patients, the rate of complete responders was higher among sEOC patients (P = 0.023). After a median follow-up of 61.1 months, median survival and time to tumor progression were not significantly different between the two groups (25.1 months [95% CI 11.7 to 38.5 months] versus 49.1 months [95% CI 36.5 to 61.6 months], P = 0.141, 12.0 months [95% CI 6.5 to 17.3 months] versus 18.0 months [95% CI 14.7 to 21.6 months], P = 0.384, respectively). CONCLUSION: Patients with OCCC have significantly lower response to platinum-based first-line chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in significantly shorter survival. The current study outcomes are provocative and suggest that a new strategy for chemotherapy in OCCC should be adopted, possibly one that focuses on new agents without cross-resistance to platinum agents.en
heal.journalNameGynecol Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Pectasides-2006-Advanced stage clear.pdf152.11 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons